RESUMEN
BACKGROUND: As many clinical laboratories convert between Stokes, Clinical and Laboratory Standards Institute (CLSI) and European Committee for Antimicrobial Susceptibility Testing (EUCAST) methods, the problem of comparing differently derived sets of antimicrobial susceptibility testing (AST) data with each other arises, owing to a scarcity of knowledge of inter-method comparability. The purpose of the current study was to determine the comparability of CLSI, EUCAST and Stokes AST methods for determining susceptibility of uropathogenic Escherichia coli to ampicillin, amoxicillin-clavulanate, trimethoprim, cephradine/cephalexin, ciprofloxacin and nitrofurantoin. METHODS: A total of 100 E. coli isolates were obtained from boric acid urine samples from patients attending GP surgeries. For EUCAST and CLSI, the Kirby-Bauer disc diffusion method was used and results interpreted using the respective breakpoint guidelines. For the Stokes method, direct susceptibility testing was performed on the urine samples. RESULTS: The lowest levels of agreement were for amoxicillin-clavulanate (60%) and ciprofloxacin (89%) between the three AST methods, when using 2017 interpretive guidelines for CLSI and EUCAST. A comparison of EUCAST and CLSI without Stokes showed 82% agreement for amoxicillin-clavulanate and 94% agreement for ciprofloxacin. Discrepancies were compounded by varying breakpoint susceptibility guidelines issued during the period 2011-2017, and through the inclusion of a definition of intermediate susceptibility in some cases. CONCLUSIONS: Our data indicate that the discrepancies generated through using different AST methods and different interpretive guidelines may result in confusion and inaccuracy when prescribing treatment for urinary tract infection.
Asunto(s)
Antibacterianos/uso terapéutico , Bacteriuria/tratamiento farmacológico , Infecciones por Escherichia coli/tratamiento farmacológico , Infecciones Urinarias/tratamiento farmacológico , Escherichia coli Uropatógena/efectos de los fármacos , Combinación Amoxicilina-Clavulanato de Potasio/uso terapéutico , Ampicilina/uso terapéutico , Bacteriuria/diagnóstico , Bacteriuria/microbiología , Cefalexina/uso terapéutico , Cefradina/uso terapéutico , Ciprofloxacina/uso terapéutico , Infecciones por Escherichia coli/diagnóstico , Infecciones por Escherichia coli/microbiología , Humanos , Pruebas de Sensibilidad Microbiana/normas , Nitrofurantoína/uso terapéutico , Guías de Práctica Clínica como Asunto , Trimetoprim/uso terapéutico , Infecciones Urinarias/diagnóstico , Infecciones Urinarias/microbiología , Escherichia coli Uropatógena/crecimiento & desarrollo , Escherichia coli Uropatógena/aislamiento & purificaciónRESUMEN
This study aims to determine the in vitro susceptibility of Helicobacter pylori to clarithromycin, metronidazole, amoxycillin and tetracycline, the four antibiotics commonly used in eradication therapies. These data are used to evaluate the efficacy of current empiric treatment of H. pylori infection in the Southern Region of Ireland. Culture is performed on gastric biopsy samples obtained from 147 consecutive patients undergoing gastroscopy for investigation of dyspepsia. Susceptibility testing to metronidazole, clarithromycin, amoxycillin and tetracycline is performed on the isolates by Etest. Isolates demonstrating clarithromycin resistance are subjected to polymerase chain reaction (PCR) amplification and nucleotide sequence analysis to identify the presence of point mutations in the peptidyltransferase region of the 23S rRNA gene previously associated with resistance to clarithromycin. Prevalence of H. pylori in the population studied was 31% (45 isolates). Antimicrobial resistance to metronidazole and clarithromycin was detected in nine (20%) and four (8.9%) of the isolates, respectively. A single isolate demonstrated co-resistance to metronidazole and clarithromycin (2.2%). No resistance was detected to either amoxycillin or tetracycline. The low level of resistance demonstrated among this group of isolates indicates that the empiric treatment currently in place in the Southern Region of Ireland is likely to be successful.
Asunto(s)
Antiinfecciosos/farmacología , Helicobacter pylori/efectos de los fármacos , Amoxicilina/farmacología , Antibacterianos/farmacología , Claritromicina/farmacología , ADN Bacteriano/genética , Farmacorresistencia Bacteriana , Helicobacter pylori/genética , Metronidazol/farmacología , Mutación , Tetraciclina/farmacologíaRESUMEN
The authors trace French psychiatric nosology since the turn of the century as it has developed clinical concepts not generally recognized by American psychiatrists. They claim the autonomy of three distinct (non-schizophrenic) chronic delusional psychoses is supported by clinical and statistical data, although current diagnostic practice fails to apply the same criteria to the differentiation of (non-schizophrenic) acute delusional psychoses, also recognized in France as an autonomous group. The authors suggest that French clinical findings have interesting practical implications for the study and treatment of that group of patients diagnosed in America as schizophrenics, a significant percentage of whom would be expected spontaneous remission without treatment.